Semaglutide Use Tied to 21% Fall in Bipolar Psychiatric Hospitalizations

Researchers at Griffith University identified a 21 percent reduction in the risk of psychiatric hospitalization among people with bipolar disorder who used semaglutide—the active ingredient in Ozempic and Wegovy—according to a nationwide Swedish cohort study spanning 15 years.

Semaglutide’s Association With Lower Hospitalization Rates

The analysis covered nearly 15,000 individuals diagnosed with bipolar disorder who received at least one prescription for a glucagon-like peptide 1 receptor agonist (GLP-1RA) between 2009 and 2024. Led by Professor Mark Taylor of Griffith University’s School of Medicine and Dentistry, the team examined anonymized national health registry data to compare hospitalization rates during periods of GLP-1RA use versus non-use.

“People with bipolar disorder who were taking semaglutide (otherwise known as Ozempic or Wegovy), a type of GLP-1 medication, had significantly lower rates of psychiatric hospitalization compared with periods when they were not taking GLP-1 medicines,” Professor Taylor said.

The observed association applied specifically to semaglutide. No comparable reduction was found for liraglutide or dulaglutide—two other GLP-1RAs included in the study.

Bipolar Disorder and Comorbid Conditions

Bipolar disorder affects an estimated 37 million people worldwide, or approximately one in 200 individuals, per the latest World Health Organization data. The condition is characterized by recurrent episodes of depression and abnormally elevated or irritable mood; severe episodes may necessitate inpatient psychiatric care.

Diabetes and obesity occur at higher-than-average rates among people with bipolar disorder. While contributing factors include lifestyle, medication side effects, genetics, and other variables, shared biological mechanisms—such as inflammation, metabolic dysregulation, and cellular stress—may underlie this overlap.

Potential Neurobiological Mechanisms

GLP-1 receptor agonists mimic a naturally occurring hormone involved in blood sugar regulation, digestion, and appetite control. Emerging research suggests the same signaling pathway may also modulate inflammatory responses and cellular stress processes in the brain.

The study authors hypothesize that semaglutide’s influence on neuroinflammation and neuronal stress pathways could contribute to mood stabilization and reduced relapse risk in bipolar disorder. They emphasize that these mechanisms remain theoretical and require experimental validation.

“The findings add to growing evidence that GLP-1 receptor agonists may have benefits beyond diabetes and obesity treatment and could represent a promising new avenue for bipolar research.”

Next Steps: A Controlled Trial Needed

Professor Taylor stated that the next critical step is a randomized controlled trial to determine whether semaglutide directly improves psychiatric outcomes in bipolar disorder—and whether it might eventually be integrated into clinical care protocols.

The study, titled “Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024,” was published on 21 June 2026 in Acta Psychiatrica Scandinavica.

Authors include Heidi Taipale, Mark Taylor, Markku Lähteenvuo, Ellenor Mittendorfer-Rutz, Antti Tanskanen, and Jari Tiihonen. DOI: 10.1111/acps.70120.